The use of bicarbonate-sulphate-calcium-magnesium and sodium-low drinkable water improves functional gastrointestinal symptoms in patients with non-alcoholic fatty liver disease: A prospective study

Gravina, Antonietta Gerarda; Pellegrino, Raffaele; Romeo, Mario; Ventriglia, Lorenzo; Scognamiglio, Flavia; Tuccillo, Concetta; Loguercio, Carmelina; Federico, Alessandro

doi:10.1016/j.clnesp.2023.07.008

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no significant changes were observed in the degree of steatosis, insulin resistance, transaminase levels, or BMI values. Notably, the study reported a significant reduction in the microbiota genus of Blautia, Collinsella, and Bifidobacterium adolescentis, typically decreased in MASLD, while an increase was observed in the genus of Subdoligranulum and Dorea, typically decreased in MASLD patients (35). And furthermore, Gravina et al (36) also reported a positive impact on functional gastrointestinal symptoms in patients with MASLD.…”

Section: Discussionmentioning

confidence: 86%

Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study

Ortiz-López,

Madrid,

Aleman

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Background/aimsThe metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity are frequent comorbidities with a high prevalence worldwide. Their pathogenesis are multifactorial, including intestinal dysbiosis. The role of small intestinal bacterial overgrowth (SIBO) in MASLD progression in obese patients remains unknown. We aimed to determine the association between SIBO and the severity of MASLD in obese patients.MethodsAn observational and cross-sectional study was conducted in obese patients, diagnosed with or without MASLD by liver biopsy. Metabolic dysfunction-associated steatotic liver (MASL), metabolic dysfunction-associated steatohepatitis without fibrosis (MASH-NF), MASH with fibrosis (MASH-F), or without MASLD (control subjects, CS) were identified by presence of steatosis, portal and lobular inflammation, and fibrosis. SIBO was determined by standardized lactulose breath tests.ResultsA total of 59 patients with MASLD, 16 with MASL, 20 with MASH-NF, 23 with MASH-F, and 14 CS were recruited. Higher percentages of SIBO were observed in MASLD patients (44.2%) compared to CS (14.2%; p = 0.0363). Interestingly, MASH-F showed higher percentages of SIBO (65.2%) in comparison to non-fibrotic MASLD (33.3%; p = 0.0165). The presence of SIBO was not correlated with the level of hepatic steatosis in MASLD patients.ConclusionsA positive correlation between MASLD and SIBO in obese patients was principally explained by the presence of liver fibrosis. Our findings suggest a pathogenic role of intestinal dysbiosis in the progression of MASLD. Future research will elucidate the underlying mechanisms of SIBO in MASLD advancement.

show abstract

Section: Discussionmentioning

confidence: 86%